

**Patient Name:** 남용범  
**Gender:** Male  
**Sample ID:** N26-87

**Primary Tumor Site:** liver  
**Collection Date:** 2026.02.11

## Sample Cancer Type: Intrahepatic Cholangiocarcinoma

Table of Contents	Page	Report Highlights
Variant Details	2	1 Relevant Biomarkers
Biomarker Descriptions	2	2 Therapies Available
Alert Details	5	27 Clinical Trials
Relevant Therapy Summary	11	

## Relevant Intrahepatic Cholangiocarcinoma Findings

Gene	Finding	Gene	Finding
BRAF	None detected	NTRK1	None detected
ERBB2	None detected	NTRK2	None detected
FGFR2	None detected	NTRK3	None detected
IDH1	None detected	RET	None detected
KRAS	<b>KRAS p.(G12D) c.35G&gt;A</b>		

  

Genomic Alteration	Finding
Tumor Mutational Burden	<b>3.79 Mut/Mb measured</b>

## Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IIC	<b>KRAS p.(G12D) c.35G&gt;A</b> KRAS proto-oncogene, GTPase Allele Frequency: 20.52% Locus: chr12:25398284 Transcript: NM_033360.4	None*	<b>avutemetinib + defactinib</b> <sup>1 / II+</sup> bevacizumab + chemotherapy <sup>1</sup>	27

\* Public data sources included in relevant therapies: FDA<sup>1</sup>, NCCN, EMA<sup>2</sup>, ESMO

\* Public data sources included in prognostic and diagnostic significance: NCCN, ESMO

Line of therapy: I: First-line therapy, II+: Other line of therapy

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

## Prevalent cancer biomarkers without relevant evidence based on included data sources

Microsatellite stable, FAT1 p.(T2369Rfs\*2) c.7105delA, HLA-A deletion, HLA-B deletion, Tumor Mutational Burden

## Variant Details

### DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect
KRAS	p.(G12D)	c.35G>A	COSM521	chr12:25398284	20.52%	NM_033360.4	missense
FAT1	p.(T2369Rfs*2)	c.7105delA	.	chr4:187540634	30.96%	NM_005245.4	frameshift Deletion
TGFBR2	p.(D549G)	c.1646A>G	.	chr3:30732958	11.57%	NM_001024847.2	missense
MSH3	p.(I945L)	c.2833A>T	.	chr5:80149968	48.12%	NM_002439.5	missense
APC	p.(C447S)	c.1339T>A	.	chr5:112157619	11.78%	NM_000038.6	missense
HLA-C	p.([V319A;V320F])	c.956_958delTTGinsCT T	.	chr6:31237800	2.08%	NM_001243042.1	missense, missense
HLA-B	p.([T118I;L119I])	c.353_355delCCCinsT CA	.	chr6:31324208	99.69%	NM_005514.8	missense, missense
NOTCH4	p.(V1954G)	c.5861T>G	.	chr6:32163365	65.84%	NM_004557.4	missense
ACVR1B	p.(?)	c.811+1G>A	.	chr12:52374984	25.22%	NM_020328.4	unknown

### Copy Number Variations

Gene	Locus	Copy Number	CNV Ratio
HLA-A	chr6:29910229	0.28	0.66
HLA-B	chr6:31322252	0	0.59

## Biomarker Descriptions

### KRAS p.(G12D) c.35G>A

*KRAS* proto-oncogene, GTPase

**Background:** The KRAS proto-oncogene encodes a GTPase that functions in signal transduction and is a member of the RAS superfamily which also includes NRAS and HRAS<sup>1</sup>. RAS proteins mediate the transmission of growth signals from the cell surface to the nucleus via the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways, which regulate cell division, differentiation, and survival<sup>10,11,12</sup>. Germline mutations in KRAS lead to several genetic disorders known as RASopathies, including Noonan syndrome, which results in heart and congenital defects, growth inhibition, and facial dysmorphic features<sup>13</sup>. Somatic mutations in KRAS are commonly altered in several cancers including non-small cell lung cancer, pancreatic cancer, and multiple myeloma<sup>13</sup>.

**Alterations and prevalence:** The majority of KRAS mutations consist of point mutations occurring at G12, G13, and Q61<sup>8,14,15</sup>. Mutations at A59, K117, and A146 have also been observed but are less frequent<sup>9,16</sup>. Somatic mutations in KRAS are observed in 66% of pancreatic adenocarcinoma, 41% of colorectal adenocarcinoma, 30% of lung adenocarcinoma, 19% of uterine corpus endometrial carcinoma, 12% of uterine carcinosarcoma, 9% of stomach adenocarcinoma, 8% of testicular germ cell tumors, 6% of cholangiocarcinoma, 5% of cervical squamous cell carcinoma, acute myeloid leukemia, and diffuse large B-cell lymphoma, 4% of bladder urothelial carcinoma, and 2% of skin cutaneous melanoma and kidney renal papillary cell carcinoma<sup>8,9</sup>. KRAS is amplified in 9% of ovarian serous cystadenocarcinoma and testicular germ cell tumors, 8% of stomach adenocarcinoma, 7% of esophageal adenocarcinoma and uterine carcinosarcoma, 6% of lung adenocarcinoma, 4% of pancreatic adenocarcinoma and bladder urothelial carcinoma, 3% of lung squamous cell carcinoma, and 2% of sarcoma, mesothelioma, brain lower grade glioma, and uterine corpus endometrial carcinoma<sup>8,9</sup>. Alterations in KRAS are also observed in pediatric cancers<sup>9</sup>. Somatic mutations in KRAS are observed in 10% of B-lymphoblastic leukemia/lymphoma (24 in 252 cases), 8% of leukemia (29 in 354 cases), and in less than 1% of embryonal tumors (2 in 332 cases), glioma (1 in 297 cases), Wilms tumor (1 in 710 cases), and peripheral nervous system cancers (1 in 1158 cases)<sup>9</sup>. KRAS is amplified in less than 1% of B-lymphoblastic leukemia/lymphoma (1 in 731 cases)<sup>9</sup>. Structural alterations in KRAS are observed in less than 1% of acute lymphoblastic leukemia (1 in 85 cases)<sup>9</sup>.

## Biomarker Descriptions (continued)

**Potential relevance:** The FDA has approved the small molecule inhibitors, sotorasib<sup>17</sup> (2021) and adagrasib<sup>18</sup> (2022), for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib and adagrasib are also useful in certain circumstances for KRAS G12C-mutated pancreatic adenocarcinoma<sup>19</sup>. The FDA has approved the combination of kinase inhibitors, avutometinib and defactinib<sup>20</sup> (2025), for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy. The FDA has granted breakthrough therapy designation (2022) to the KRAS G12C inhibitor, GDC-6036<sup>21</sup>, for KRAS G12C-mutated NSCLC. The KRAS-G12C/NRAS-G12C dual inhibitor, elironrasib<sup>22</sup>, and the KRAS G12C inhibitor, D3S-001<sup>23</sup>, were both granted breakthrough therapy designation (2025) for KRAS G12C-mutated locally advanced or metastatic NSCLC in adults previously treated with chemotherapy and immunotherapy, excluding KRAS G12C inhibitors. The KRAS-G12C inhibitor, olomorasib<sup>24</sup>, was granted breakthrough designation (2025) in combination with pembrolizumab<sup>25</sup> for unresectable advanced or metastatic NSCLC with a KRAS G12C mutation and PD-L1 expression  $\geq$  50%. The RAF/MEK clamp, avutometinib<sup>26</sup> was also granted fast track designation (2024) in combination with sotorasib for KRAS G12C-mutated metastatic NSCLC in patients who have received at least one prior systemic therapy and have not been previously treated with a KRAS G12C inhibitor. The KRAS G12C inhibitor, BBO-8520<sup>27</sup>, was granted fast track designation in 2025 for previously treated KRAS G12C-mutated patients with metastatic NSCLC. The RAS inhibitor, daraxonrasib<sup>28</sup>, was granted breakthrough designation (2025) for previously treated metastatic pancreatic cancer with KRAS G12 mutations. The KRAS G12D (ON/OFF) inhibitor, GFH-375<sup>29</sup>, was also granted fast track designation (2025) for first-line and previously treated KRAS G12D-mutated locally advanced or metastatic pancreatic adenocarcinoma. The KRAS G12C inhibitor, D3S-001<sup>30</sup>, was granted fast track designation in 2024 for KRAS G12C-mutated patients with advanced unresectable or metastatic colorectal cancers. The PLK1 inhibitor, onvansertib<sup>31</sup>, was granted fast track designation (2020) in combination with bevacizumab and FOLFIRI for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The EGFR antagonists, cetuximab<sup>32</sup> and panitumumab<sup>33</sup>, are contraindicated for treatment of colorectal cancer patients with KRAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146)<sup>16</sup>. Additionally, KRAS mutations are associated with poor prognosis in NSCLC<sup>34</sup>.

### Microsatellite stable

**Background:** Microsatellites are short tandem repeats (STR) of 1 to 6 bases of DNA between 5 to 50 repeat units in length. There are approximately 0.5 million STRs that occupy 3% of the human genome<sup>35</sup>. Microsatellite instability (MSI) is defined as a change in the length of a microsatellite in a tumor as compared to normal tissue<sup>36,37</sup>. MSI is closely tied to the status of the mismatch repair (MMR) genes. In humans, the core MMR genes include MLH1, MSH2, MSH6, and PMS2<sup>38</sup>. Mutations and loss of expression in MMR genes, known as defective MMR (dMMR), lead to MSI. In contrast, when MMR genes lack alterations, they are referred to as MMR proficient (pMMR). Consensus criteria were first described in 1998 and defined MSI-high (MSI-H) as instability in two or more of the following five markers: BAT25, BAT26, D5S346, D2S123, and D17S250<sup>39</sup>. Tumors with instability in one of the five markers were defined as MSI-low (MSI-L) whereas, those with instability in zero markers were defined as MS-stable (MSS)<sup>39</sup>. Tumors classified as MSI-L are often phenotypically indistinguishable from MSS tumors and tend to be grouped with MSS<sup>40,41,42,43,44</sup>. MSI-H is a hallmark of Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, which is caused by germline mutations in the MMR genes<sup>37</sup>. LS is associated with an increased risk of developing colorectal cancer, as well as other cancers, including endometrial and stomach cancer<sup>36,37,41,45</sup>.

**Alterations and prevalence:** The MSI-H phenotype is observed in 30% of uterine corpus endothelial carcinoma, 20% of stomach adenocarcinoma, 15-20% of colon adenocarcinoma, and 5-10% of rectal adenocarcinoma<sup>36,37,46,47</sup>. MSI-H is also observed in 5% of adrenal cortical carcinoma and at lower frequencies in other cancers such as esophageal, liver, and ovarian cancers<sup>46,47</sup>.

**Potential relevance:** Anti-PD-1 immune checkpoint inhibitors including pembrolizumab<sup>25</sup> (2014) and nivolumab<sup>48</sup> (2015) are approved for patients with MSI-H or dMMR colorectal cancer who have progressed following chemotherapy. Pembrolizumab<sup>25</sup> is also approved as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR with disease progression on prior therapy who are not candidates for surgery or radiation. Importantly, pembrolizumab is approved for the treatment of MSI-H or dMMR solid tumors that have progressed following treatment, with no alternative option and is the first anti-PD-1 inhibitor to be approved with a tumor agnostic indication<sup>25</sup>. Dostarlimab<sup>49</sup> (2021) is also approved for dMMR recurrent or advanced endometrial carcinoma or solid tumors that have progressed on prior treatment and is recommended as a subsequent therapy option in dMMR/MSI-H advanced or metastatic colon or rectal cancer<sup>42,50</sup>. The cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody, ipilimumab<sup>51</sup> (2011), is approved alone or in combination with nivolumab in MSI-H or dMMR colorectal cancer that has progressed following treatment with chemotherapy. MSI-H may confer a favorable prognosis in colorectal cancer although outcomes vary depending on stage and tumor location<sup>42,52,53</sup>. Specifically, MSI-H is a strong prognostic indicator of better overall survival (OS) and relapse free survival (RFS) in stage II as compared to stage III colorectal cancer patients<sup>53</sup>. The majority of patients with tumors classified as either MSS or pMMR do not benefit from treatment with single-agent immune checkpoint inhibitors as compared to those with MSI-H tumors<sup>54,55</sup>. However, checkpoint blockade with the addition of chemotherapy or targeted therapies have demonstrated response in MSS or pMMR cancers<sup>54,55</sup>.

## Biomarker Descriptions (continued)

### FAT1 p.(T2369Rfs\*2) c.7105delA

*FAT atypical cadherin 1*

**Background:** FAT1 encodes the FAT atypical cadherin 1 protein, a member of the cadherin superfamily characterized by the presence of cadherin-type repeats<sup>1,56</sup>. FAT cadherins, which also include FAT2, FAT3, and FAT4, are transmembrane proteins containing a cytoplasmic domain and a number of extracellular laminin G-like motifs and EGF-like motifs, which contributes to their individual functions<sup>56</sup>. The cytoplasmic tail of FAT1 is known to interact with a number of protein targets involved in cell adhesion, proliferation, migration, and invasion<sup>56</sup>. FAT1 has been observed to influence the regulation of several oncogenic pathways, including the WNT/ $\beta$ -catenin, Hippo, and MAPK/ERK signaling pathways, as well as epithelial to mesenchymal transition<sup>56</sup>. Alterations of FAT1 lead to down-regulation or loss of function, supporting a tumor suppressor role for FAT1<sup>56</sup>.

**Alterations and prevalence:** Somatic mutations in FAT1 are predominantly truncating although, the R1627Q mutation has been identified as a recurrent hotspot<sup>8,9</sup>. Mutations in FAT1 are observed in 22% of head and neck squamous cell carcinoma, 20% of uterine corpus endometrial carcinoma, 14% of lung squamous cell carcinoma and skin cutaneous melanoma, and 12% diffuse large b-cell lymphoma and bladder urothelial carcinoma<sup>8,9</sup>. Biallelic loss of FAT1 is observed in 7% of head and neck squamous cell carcinoma, 6% of lung squamous cell carcinoma, 5% of esophageal adenocarcinoma, and 4% of diffuse large b-cell lymphoma, stomach adenocarcinoma and uterine carcinosarcoma<sup>8,9</sup>.

**Potential relevance:** Currently, no therapies are approved for FAT1 aberrations.

### HLA-A deletion

*major histocompatibility complex, class I, A*

**Background:** The HLA-A gene encodes the major histocompatibility complex, class I, A<sup>1</sup>. MHC (major histocompatibility complex) class I molecules are located on the cell surface of nucleated cells and present antigens from within the cell for recognition by cytotoxic T cells<sup>2</sup>. MHC class I molecules are heterodimers composed of two polypeptide chains,  $\alpha$  and B2M<sup>3</sup>. The classical MHC class I genes include HLA-A, HLA-B, and HLA-C and encode the  $\alpha$  polypeptide chains, which present short polypeptide chains, of 7 to 11 amino acids, to the immune system to distinguish self from non-self<sup>4,5,6</sup>. Downregulation of MHC class I promotes tumor evasion of the immune system, suggesting a tumor suppressor role for HLA-A<sup>7</sup>.

**Alterations and prevalence:** Somatic mutations in HLA-A are observed in 7% of diffuse large B-cell lymphoma (DLBCL), 4% of cervical squamous cell carcinoma and head and neck squamous cell carcinoma, 3% of colorectal adenocarcinoma, and 2% of uterine corpus endometrial carcinoma and stomach adenocarcinoma<sup>8,9</sup>. Biallelic loss of HLA-A is observed in 4% of DLBCL<sup>8,9</sup>.

**Potential relevance:** Currently, no therapies are approved for HLA-A aberrations.

### HLA-B deletion

*major histocompatibility complex, class I, B*

**Background:** The HLA-B gene encodes the major histocompatibility complex, class I, B<sup>1</sup>. MHC (major histocompatibility complex) class I molecules are located on the cell surface of nucleated cells and present antigens from within the cell for recognition by cytotoxic T cells<sup>2</sup>. MHC class I molecules are heterodimers composed of two polypeptide chains,  $\alpha$  and B2M<sup>3</sup>. The classical MHC class I genes include HLA-A, HLA-B, and HLA-C and encode the  $\alpha$  polypeptide chains, which present short polypeptide chains, of 7 to 11 amino acids, to the immune system to distinguish self from non-self<sup>4,5,6</sup>. Downregulation of MHC class I promotes tumor evasion of the immune system, suggesting a tumor suppressor role for HLA-B<sup>7</sup>.

**Alterations and prevalence:** Somatic mutations in HLA-B are observed in 10% of diffuse large B-cell lymphoma (DLBCL), 5% of cervical squamous cell carcinoma and stomach adenocarcinoma, 4% of head and neck squamous cell carcinoma and colorectal adenocarcinoma, 3% of uterine cancer, and 2% of esophageal adenocarcinoma and skin cutaneous melanoma<sup>8,9</sup>. Biallelic loss of HLA-B is observed in 5% of DLBCL<sup>8,9</sup>.

**Potential relevance:** Currently, no therapies are approved for HLA-B aberrations.

## Alerts Informed By Public Data Sources

### Current FDA Information

 Contraindicated    Not recommended    Resistance    Breakthrough    Fast Track

FDA information is current as of 2025-11-25. For the most up-to-date information, search [www.fda.gov](http://www.fda.gov).

### KRAS p.(G12D) c.35G>A

#### cetuximab

**Cancer type:** Colorectal Cancer

**Label as of:** 2021-09-24

**Variant class:** KRAS G12 mutation

##### Indications and usage:

Erbix® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:

##### Head and Neck Cancer

- Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.
- Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil.
- Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.

##### Colorectal Cancer

K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by FDA-approved test

- in combination with FOLFIRI for first-line treatment,
- in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy,
- as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.

**Limitations of Use:** Erbix® is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown.

##### BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)

- in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

##### Reference:

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/125084s279lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

**KRAS p.(G12D) c.35G>A (continued)****🚫 panitumumab****Cancer type:** Colorectal Cancer**Label as of:** 2025-01-16**Variant class:** KRAS G12 mutation**Indications and usage:**

VECTIBIX® is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of:

Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC)\*:

- In combination with FOLFOX for first-line treatment.
- As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.

KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)\*

- In combination with sotorasib, for the treatment of adult patients with KRAS G12C-mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

\*Limitations of Use: VECTIBIX® is not indicated for the treatment of patients with RAS-mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC. VECTIBIX® is not indicated for the treatment of patients with mCRC for whom RAS mutation status is unknown.

**Reference:**

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/125147s213lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125147s213lbl.pdf)

**🦋 daraxonrasib****Cancer type:** Pancreatic Cancer**Variant class:** KRAS G12 mutation**Supporting Statement:**

The FDA has granted Breakthrough designation to the RAS inhibitor, daraxonrasib, for previously treated metastatic pancreatic adenocarcinoma (PDAC) in patients with KRAS G12 mutations.

**Reference:**

<https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-fda-breakthrough-therapy>

**⚡ GFH-375****Cancer type:** Pancreatic Cancer**Variant class:** KRAS G12D mutation**Supporting Statement:**

The FDA has granted Fast Track designation to an oral KRAS G12D (ON/OFF) inhibitor, GFH-375 (VS-7375), for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) and for the treatment of patients with KRAS G12D-mutated locally advanced or metastatic PDAC who have received at least one prior line of standard systemic therapy.

**Reference:**

<https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-granted-fast-track-designation-vs-7375>

## Current NCCN Information

 Contraindicated    Not recommended    Resistance    Breakthrough    Fast Track

NCCN information is current as of 2025-11-03. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org).

For NCCN International Adaptations & Translations, search [www.nccn.org/global/what-we-do/international-adaptations](https://www.nccn.org/global/what-we-do/international-adaptations).

Some variant specific evidence in this report may be associated with a broader set of alterations from the NCCN Guidelines. Specific variants listed in this report were sourced from approved therapies or scientific literature. These therapeutic options are appropriate for certain population segments with cancer. Refer to the NCCN Guidelines® for full recommendation.

All guidelines cited below are referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) National Comprehensive Cancer Network, Inc. 2023. All rights reserved. NCCN makes no warranties regarding their content.

### KRAS p.(G12D) c.35G>A

#### cetuximab

Cancer type: Colon Cancer

Variant class: KRAS G12 mutation

##### Summary:

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab, unless given as part of a regimen targeting a KRAS G12C mutation."

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 5.2025]

#### cetuximab

Cancer type: Rectal Cancer

Variant class: KRAS G12 mutation

##### Summary:

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exons 2, 3, and 4) or NRAS mutation (exons 2, 3, and 4) should not be treated with either cetuximab or panitumumab, unless given as part of a regimen targeting a KRAS G12C mutation."

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 4.2025]

#### panitumumab

Cancer type: Colon Cancer

Variant class: KRAS G12 mutation

##### Summary:

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab, unless given as part of a regimen targeting a KRAS G12C mutation."

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 5.2025]

**KRAS p.(G12D) c.35G>A (continued)****⊘ panitumumab**

Cancer type: Rectal Cancer

Variant class: KRAS G12 mutation

**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exons 2, 3, and 4) or NRAS mutation (exons 2, 3, and 4) should not be treated with either cetuximab or panitumumab, unless given as part of a regimen targeting a KRAS G12C mutation."

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 4.2025]

**Current EMA Information**

⊘ Contraindicated    ⊖ Not recommended    🛡 Resistance    🚀 Breakthrough    ⚡ Fast Track

EMA information is current as of 2025-11-25. For the most up-to-date information, search [www.ema.europa.eu](http://www.ema.europa.eu).**KRAS p.(G12D) c.35G>A****⊘ cetuximab, cetuximab + oxaliplatin**

Cancer type: Colorectal Cancer

Label as of: 2025-01-16

Variant class: KRAS G12 mutation

**Reference:**[https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf)**⊘ panitumumab + oxaliplatin**

Cancer type: Colorectal Cancer

Label as of: 2025-05-07

Variant class: KRAS G12 mutation

**Reference:**[https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf)

## Current ESMO Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

ESMO information is current as of 2025-11-03. For the most up-to-date information, search [www.esmo.org](http://www.esmo.org).

### KRAS p.(G12D) c.35G>A

#### cetuximab

Cancer type: Colorectal Cancer

Variant class: KRAS G12 mutation

##### Summary:

ESMO Clinical Practice Guidelines include the following supporting statement:

- "The presence of RAS mutations is associated with resistance to anti-EGFR mAbs and knowing the expanded RAS mutational status is mandatory for use of both cetuximab and panitumumab, avoiding anti-EGFR mAb treatment when a RAS mutation is confirmed".
- "RAS testing is mandatory before treatment with anti-EGFR mAbs and can be carried out on either the primary tumor or other metastatic sites [III, A]".

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2023); <https://doi.org/10.1016/j.annonc.2022.10.003> (published)]

#### panitumumab

Cancer type: Colorectal Cancer

Variant class: KRAS G12 mutation

##### Summary:

ESMO Clinical Practice Guidelines include the following supporting statement:

- "The presence of RAS mutations is associated with resistance to anti-EGFR mAbs and knowing the expanded RAS mutational status is mandatory for use of both cetuximab and panitumumab, avoiding anti-EGFR mAb treatment when a RAS mutation is confirmed".
- "RAS testing is mandatory before treatment with anti-EGFR mAbs and can be carried out on either the primary tumor or other metastatic sites [III, A]".

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2023); <https://doi.org/10.1016/j.annonc.2022.10.003> (published)]

## Genes Assayed

### Genes Assayed for the Detection of DNA Sequence Variants

ABL1, ABL2, ACVR1, AKT1, AKT2, AKT3, ALK, AR, ARAF, ATP1A1, AURKA, AURKB, AURKC, AXL, BCL2, BCL2L12, BCL6, BCR, BMP5, BRAF, BTK, CACNA1D, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD79B, CDK4, CDK6, CHD4, CSF1R, CTNNB1, CUL1, CYSLTR2, DDR2, DGCR8, DROSHA, E2F1, EGFR, EIF1AX, EPAS1, ERBB2, ERBB3, ERBB4, ESR1, EZH2, FAM135B, FGF7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FOXL2, FOXO1, GATA2, GLI1, GNA11, GNAQ, GNAS, HIF1A, HRAS, IDH1, IDH2, IKBKB, IL6ST, IL7R, IRF4, IRS4, KCNJ5, KDR, KIT, KLF4, KLF5, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAPK1, MAX, MDM4, MECOM, MED12, MEF2B, MET, MITF, MPL, MTOR, MYC, MYCN, MYD88, MYO10, NFE2L2, NRAS, NSD2, NT5C2, NTRK1, NTRK2, NTRK3, NUP93, PAX5, PCBP1, PDGFRA, PDGFRB, PIK3C2B, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R2, PIM1, PLCG1, PPP2R1A, PPP6C, PRKACA, PTPN11, PTPRD, PXDNL, RAC1, RAF1, RARA, RET, RGS7, RHEB, RHOA, RICTOR, RIT1, ROS1, RPL10, SETBP1, SF3B1, SIX1, SIX2, SLC01B3, SMC1A, SMO, SNCAIP, SOS1, SOX2, SPOP, SRC, SRSF2, STAT3, STAT5B, STAT6, TAF1, TERT, TGFB1, TOP1, TOP2A, TPMT, TRRAP, TSHR, U2AF1, USP8, WAS, XPO1, ZNF217, ZNF429

## Genes Assayed (continued)

### Genes Assayed for the Detection of Copy Number Variations

ABCB1, ABL1, ABL2, ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AKT1, AKT2, AKT3, ALK, AMER1, APC, AR, ARAF, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKC, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BCL2, BCL2L12, BCL6, BCOR, BLM, BMPR2, BRAF, BRCA1, BRCA2, BRIP1, CARD11, CASP8, CBF, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHD4, CHEK1, CHEK2, CIC, CREBBP, CSMD3, CTCF, CTLA4, CTNND2, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, DAXX, DDR1, DDR2, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, EGFR, EIF1AX, ELF3, EMSY, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERBB2, ERBB3, ERBB4, ERCC2, ERCC4, ERRF1, ESR1, ETV6, EZH2, FAM135B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAT1, FBXW7, FGF19, FGF23, FGF3, FGF4, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, FUBP1, FYN, GATA2, GATA3, GLI3, GNA13, GNAS, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, IDH2, IGF1R, IKBKB, IL7R, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KDR, KEAP1, KIT, KLF5, KMT2A, KMT2B, KMT2C, KMT2D, KRAS, LARP4B, LATS1, LATS2, MAGOH, MAP2K1, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK1, MAPK8, MAX, MCL1, MDM2, MDM4, MECOM, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLH3, MPL, MRE11, MSH2, MSH3, MSH6, MTAP, MTOR, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NCOR1, NF1, NF2, NFE2L2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NRAS, NTRK1, NTRK3, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PCBP1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDIA3, PGD, PHF6, PIK3C2B, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PIM1, PLCG1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PRDM9, PRKACA, PRKAR1A, PTCH1, PTEN, PTPN11, PTPRT, PXDNL, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RARA, RASA1, RASA2, RB1, RBM10, RECQL4, RET, RHEB, RICTOR, RIT1, RNASEH2A, RNASEH2B, RNF43, ROS1, RPA1, RPS6KB1, RPTOR, RUNX1, SDHA, SDHB, SDHD, SETBP1, SETD2, SF3B1, SLCO1B3, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SMC1A, SMO, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STAT6, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TERT, TET2, TGFB2, TNFAIP3, TNFRSF14, TOP1, TP53, TP63, TPMT, TPP2, TSC1, TSC2, U2AF1, USP8, USP9X, VHL, WT1, XPO1, XRCC2, XRCC3, YAP1, YES1, ZFH3, ZMYM3, ZNF217, ZNF429, ZRSR2

### Genes Assayed for the Detection of Fusions

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT

### Genes Assayed with Full Exon Coverage

ABRAXAS1, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AMER1, APC, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AXIN1, AXIN2, B2M, BAP1, BARD1, BCOR, BLM, BMPR2, BRCA1, BRCA2, BRIP1, CALR, CASP8, CBF, CD274, CD276, CDC73, CDH1, CDH10, CDK12, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHEK1, CHEK2, CIC, CIITA, CREBBP, CSMD3, CTCF, CTLA4, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, CYP2D6, DAXX, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, ELF3, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERAP2, ERCC2, ERCC4, ERCC5, ERRF1, ETV6, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FAT1, FBXW7, FUBP1, GATA3, GNA13, GPS2, HDAC2, HDAC9, HLA-A, HLA-B, HNF1A, ID3, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KEAP1, KLHL13, KMT2A, KMT2B, KMT2C, KMT2D, LARP4B, LATS1, LATS2, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK8, MEN1, MGA, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MTAP, MTUS2, MUTYH, NBN, NCOR1, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PALB2, PARP1, PARP2, PARP3, PARP4, PBRM1, PDCD1, PDCD1LG2, PDIA3, PGD, PHF6, PIK3R1, PMS1, PMS2, POLD1, POLE, POT1, PPM1D, PPP2R2A, PRDM1, PRDM9, PRKAR1A, PSMB10, PSMB8, PSMB9, PTCH1, PTEN, PTPRT, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RASA1, RASA2, RB1, RBM10, RECQL4, RNASEH2A, RNASEH2B, RNASEH2C, RNF43, RPA1, RPL22, RPL5, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SOCS1, SOX9, SPEN, STAG2, STAT1, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TET2, TGFB2, TMEM132D, TNFAIP3, TNFRSF14, TP53, TP63, TPP2, TSC1, TSC2, UGT1A1, USP9X, VHL, WT1, XRCC2, XRCC3, ZBTB20, ZFH3, ZMYM3, ZRSR2

## Relevant Therapy Summary

● In this cancer type    
 ○ In other cancer type    
 ① In this cancer type and other cancer types    
 ✕ No evidence

### KRAS p.(G12D) c.35G>A

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
avutometinib + defactinib	○	○	✕	✕	✕
bevacizumab + CAPOX	✕	✕	✕	○	✕
bevacizumab + FOLFIRI	✕	✕	✕	○	✕
bevacizumab + FOLFOX	✕	✕	✕	○	✕
bevacizumab + FOLFOXIRI	✕	✕	✕	○	✕
almonertinib, palbociclib	✕	✕	✕	✕	● (I/II)
ARV-806	✕	✕	✕	✕	● (I/II)
DN-022150	✕	✕	✕	✕	● (I/II)
ERAS-0015	✕	✕	✕	✕	● (I/II)
GFH-375	✕	✕	✕	✕	● (I/II)
HRS-4642, SHR-A1904, SHR-1921	✕	✕	✕	✕	● (I/II)
QLC-1101, QL1203, pembrolizumab (Qilu Pharmaceutical), iparomlimab and tuvonralimab, chemotherapy	✕	✕	✕	✕	● (I/II)
RNK-08954	✕	✕	✕	✕	● (I/II)
TSN-1611	✕	✕	✕	✕	● (I/II)
YL-15293	✕	✕	✕	✕	● (I/II)
ASP-4396	✕	✕	✕	✕	● (I)
ASP-5834	✕	✕	✕	✕	● (I)
AST-NS2101	✕	✕	✕	✕	● (I)
BPI-442096	✕	✕	✕	✕	● (I)
daraxonrasib	✕	✕	✕	✕	● (I)
GDC-7035	✕	✕	✕	✕	● (I)
HS-10529	✕	✕	✕	✕	● (I)
imatinib, trametinib	✕	✕	✕	✕	● (I)
JAB-3312	✕	✕	✕	✕	● (I)
KRAS TCR, aldesleukin, SLATE 001, chemotherapy	✕	✕	✕	✕	● (I)
Nest-1	✕	✕	✕	✕	● (I)
NT-112, AZD-0240	✕	✕	✕	✕	● (I)
PT-0253	✕	✕	✕	✕	● (I)

\* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

## Relevant Therapy Summary (continued)

In this cancer type   
  In other cancer type   
  In this cancer type and other cancer types   
  No evidence

### KRAS p.(G12D) c.35G>A (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
QLC-1101	×	×	×	×	● (I)
RMC-9805, daraxonrasib	×	×	×	×	● (I)
toripalimab, chemotherapy, KRAS peptide vaccine	×	×	×	×	● (I)
ZEN-3694, binimetinib	×	×	×	×	● (I)

\* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

## HRR Details

Gene/Genomic Alteration	Finding
LOH percentage	<b>9.97%</b>
RAD54L	<b>LOH, 1p34.1(46714017-46743978)x2</b>

Homologous recombination repair (HRR) genes were defined from published evidence in relevant therapies, clinical guidelines, as well as clinical trials, and include - BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L.

Thermo Fisher Scientific's Ion Torrent OncoPrint Reporter software was used in generation of this report. Software was developed and designed internally by Thermo Fisher Scientific. The analysis was based on OncoPrint Reporter (6.2.4 data version 2025.12(007)). The data presented here are from a curated knowledge base of publicly available information, but may not be exhaustive. FDA information was sourced from [www.fda.gov](http://www.fda.gov) and is current as of 2025-11-25. NCCN information was sourced from [www.nccn.org](http://www.nccn.org) and is current as of 2025-11-03. EMA information was sourced from [www.ema.europa.eu](http://www.ema.europa.eu) and is current as of 2025-11-25. ESMO information was sourced from [www.esmo.org](http://www.esmo.org) and is current as of 2025-11-03. Clinical Trials information is current as of 2025-11-03. For the most up-to-date information regarding a particular trial, search [www.clinicaltrials.gov](http://www.clinicaltrials.gov) by NCT ID or search local clinical trials authority website by local identifier listed in 'Other identifiers.' Variants are reported according to HGVS nomenclature and classified following AMP/ASCO/CAP guidelines (Li et al. 2017). Based on the data sources selected, variants, therapies, and trials listed in this report are listed in order of potential clinical significance but not for predicted efficacy of the therapies.

## References

1. O'Leary et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* 2016 Jan 4;44(D1):D733-45. PMID: 26553804
2. Hulpke et al. The MHC I loading complex: a multitasking machinery in adaptive immunity. *Trends Biochem Sci.* PMID: 23849087
3. Adams et al. The adaptable major histocompatibility complex (MHC) fold: structure and function of nonclassical and MHC class I-like molecules. *Annu Rev Immunol.* 2013;31:529-61. PMID: 23298204
4. Rossjohn et al. T cell antigen receptor recognition of antigen-presenting molecules. *Annu Rev Immunol.* 2015;33:169-200. PMID: 25493333
5. Parham. MHC class I molecules and KIRs in human history, health and survival. *Nat Rev Immunol.* 2005 Mar;5(3):201-14. PMID: 15719024
6. Sidney et al. HLA class I supertypes: a revised and updated classification. *BMC Immunol.* 2008 Jan 22;9:1. PMID: 18211710
7. Cornel et al. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. *Cancers (Basel).* 2020 Jul 2;12(7). PMID: 32630675
8. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
9. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
10. Pylayeva-Gupta et al. RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer.* 2011 Oct 13;11(11):761-74. PMID: 21993244
11. Karnoub et al. Ras oncogenes: split personalities. *Nat. Rev. Mol. Cell Biol.* 2008 Jul;9(7):517-31. PMID: 18568040
12. Scott et al. Therapeutic Approaches to RAS Mutation. *Cancer J.* 2016 May-Jun;22(3):165-74. doi: 10.1097/PPO.000000000000187. PMID: 27341593
13. Johnson et al. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention. *Cancer Discov.* 2022 Apr 1;12(4):913-923. PMID: 35373279
14. Román et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. *Mol Cancer.* 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. PMID: 29455666
15. Dinu et al. Prognostic significance of KRAS gene mutations in colorectal cancer—preliminary study. *J Med Life.* 2014 Oct-Dec;7(4):581-7. PMID: 25713627
16. Allegra et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J. Clin. Oncol.* 2016 Jan 10;34(2):179-85. PMID: 26438111
17. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/214665Orig1s009correctedlbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214665Orig1s009correctedlbl.pdf)
18. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/216340s005lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216340s005lbl.pdf)
19. NCCN Guidelines® - NCCN-Pancreatic Adenocarcinoma [Version 2.2025]
20. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/219616s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf)
21. <https://assets.cwp.roche.com/f/126832/x/5738a7538b/irp230202.pdf>
22. <https://ir.revmed.com/node/11881/pdf>
23. <https://www.prnewswire.com/news-releases/d3-bio-inc-announces-fda-breakthrough-therapy-designation-and-orphan-drug-designation-for-d3s-001-for-the-treatment-of-patients-with-kras-g12c-mutated-cancers-302540808.html>
24. <https://www.prnewswire.com/news-releases/lillys-olomorasib-receives-us-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-newly-diagnosed-metastatic-kras-g12c-mutant-lung-cancers-302545643.html>
25. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/125514s178lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s178lbl.pdf)
26. <https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-granted-fast-track-designation-combination>
27. <https://www.businesswire.com/news/home/20250109170439/en/>
28. <https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-fda-breakthrough-therapy>
29. <https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-granted-fast-track-designation-vs-7375>
30. <https://www.d3bio.com/press-releases/d3-bios-d3s-001-receives-u-s-fda-fast-track-designation-for-the-treatment-of-colorectal-cancer-with-kras-g12c-mutation>
31. [https://cardiffoncology.com/wp-content/uploads/2021/07/Cardiff\\_Oncology\\_Investor\\_Presentation\\_-\\_July\\_2021.pdf](https://cardiffoncology.com/wp-content/uploads/2021/07/Cardiff_Oncology_Investor_Presentation_-_July_2021.pdf)
32. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/125084s279lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)
33. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/125147s213lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125147s213lbl.pdf)

## References (continued)

34. Slebos et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. *N. Engl. J. Med.* 1990 Aug 30;323(9):561-5. PMID: 2199829
35. Lander et al. Initial sequencing and analysis of the human genome. *Nature.* 2001 Feb 15;409(6822):860-921. PMID: 11237011
36. Baudrin et al. Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer. *Front Oncol.* 2018 Dec 12;8:621. doi: 10.3389/fonc.2018.00621. eCollection 2018. PMID: 30631754
37. Nojadedeh et al. Microsatellite instability in colorectal cancer. *EXCLI J.* 2018;17:159-168. PMID: 29743854
38. Saeed et al. Microsatellites in Pursuit of Microbial Genome Evolution. *Front Microbiol.* 2016 Jan 5;6:1462. doi: 10.3389/fmicb.2015.01462. eCollection 2015. PMID: 26779133
39. Boland et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* 1998 Nov 15;58(22):5248-57. PMID: 9823339
40. Halford et al. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. *Cancer Res.* 2002 Jan 1;62(1):53-7. PMID: 11782358
41. Imai et al. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. *Carcinogenesis.* 2008 Apr;29(4):673-80. PMID: 17942460
42. NCCN Guidelines® - NCCN-Colon Cancer [Version 5.2025]
43. Pawlik et al. Colorectal carcinogenesis: MSI-H versus MSI-L. *Dis. Markers.* 2004;20(4-5):199-206. PMID: 15528785
44. Lee et al. Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer. *Medicine (Baltimore).* 2015 Dec;94(50):e2260. PMID: 26683947
45. Latham et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *J. Clin. Oncol.* 2019 Feb 1;37(4):286-295. PMID: 30376427
46. Cortes-Ciriano et al. A molecular portrait of microsatellite instability across multiple cancers. *Nat Commun.* 2017 Jun 6;8:15180. doi: 10.1038/ncomms15180. PMID: 28585546
47. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precis Oncol.* 2017;2017. PMID: 29850653
48. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/125554s131lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s131lbl.pdf)
49. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2024/761174s009lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s009lbl.pdf)
50. NCCN Guidelines® - NCCN-Rectal Cancer [Version 4.2025]
51. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2025/125377s136lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s136lbl.pdf)
52. Ribic et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N. Engl. J. Med.* 2003 Jul 17;349(3):247-57. PMID: 12867608
53. Klingbiel et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. *Ann. Oncol.* 2015 Jan;26(1):126-32. PMID: 25361982
54. Hermel et al. The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer. *J Pers Med.* 2019 Jan 16;9(1). PMID: 30654522
55. Ciardiello et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer Treat. Rev.* 2019 Jun;76:22-32. PMID: 31079031
56. Peng et al. Role of FAT1 in health and disease. *Oncol Lett.* 2021 May;21(5):398. PMID: 33777221